Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1963 1
1967 1
1968 2
1969 1
1970 1
1972 2
1975 1
1977 1
1979 1
1980 1
1981 1
1982 3
1984 1
1987 3
1988 3
1989 1
1990 7
1991 1
1992 1
1993 4
1994 2
1995 2
1996 5
1997 4
1998 7
1999 12
2000 15
2001 18
2002 24
2003 43
2004 26
2005 28
2006 28
2007 51
2008 72
2009 98
2010 108
2011 144
2012 151
2013 186
2014 188
2015 201
2016 211
2017 174
2018 172
2019 184
2020 219
2021 229
2022 212
2023 175
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

2,700 results

Results by year

Filters applied: . Clear all
Page 1
Recent Advances of Actinomycetes.
Kim ES. Kim ES. Biomolecules. 2021 Jan 21;11(2):134. doi: 10.3390/biom11020134. Biomolecules. 2021. PMID: 33494267 Free PMC article.
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.
Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G Jr, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. Judd J, et al. Among authors: kim es. Mol Cancer Ther. 2021 Dec;20(12):2577-2584. doi: 10.1158/1535-7163.MCT-21-0201. Epub 2021 Sep 13. Mol Cancer Ther. 2021. PMID: 34518295 Free PMC article.
The lowly chalazion.
Kim ES, Afshin EE, Elahi E. Kim ES, et al. Surv Ophthalmol. 2023 Jul-Aug;68(4):784-793. doi: 10.1016/j.survophthal.2022.11.002. Epub 2022 Nov 15. Surv Ophthalmol. 2023. PMID: 36395826
Small intestine and colon tissue-resident memory CD8+ T cells exhibit molecular heterogeneity and differential dependence on Eomes.
Lin YH, Duong HG, Limary AE, Kim ES, Hsu P, Patel SA, Wong WH, Indralingam CS, Liu YC, Yao P, Chiang NR, Vandenburgh SA, Anderson TR, Olvera JG, Ferry A, Takehara KK, Jin W, Tsai MS, Yeo GW, Goldrath AW, Chang JT. Lin YH, et al. Among authors: kim es. Immunity. 2023 Jan 10;56(1):207-223.e8. doi: 10.1016/j.immuni.2022.12.007. Epub 2022 Dec 28. Immunity. 2023. PMID: 36580919
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
Ou SI, Nishio M, Ahn MJ, Mok T, Barlesi F, Zhou C, Felip E, de Marinis F, Kim SW, Pérol M, Liu G, Migliorino MR, Kim DW, Novello S, Bearz A, Garrido P, Mazieres J, Morabito A, Lin HM, Yang H, Niu H, Zhang P, Kim ES. Ou SI, et al. Among authors: kim es. J Thorac Oncol. 2022 Dec;17(12):1404-1414. doi: 10.1016/j.jtho.2022.08.018. Epub 2022 Sep 10. J Thorac Oncol. 2022. PMID: 36096442 Free article.
Central serous chorioretinopathy: Treatment.
Park JB, Kim K, Kang MS, Kim ES, Yu SY. Park JB, et al. Among authors: kim es. Taiwan J Ophthalmol. 2022 Nov 28;12(4):394-408. doi: 10.4103/2211-5056.362040. eCollection 2022 Oct-Dec. Taiwan J Ophthalmol. 2022. PMID: 36660123 Free PMC article. Review.
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Kim ES, Velcheti V, Mekhail T, Yun C, Shagan SM, Hu S, Chae YK, Leal TA, Dowell JE, Tsai ML, Dakhil CSR, Stella P, Jin Y, Shames DS, Schleifman E, Fabrizio DA, Phan S, Socinski MA. Kim ES, et al. Nat Med. 2022 May;28(5):939-945. doi: 10.1038/s41591-022-01754-x. Epub 2022 Apr 14. Nat Med. 2022. PMID: 35422531 Free PMC article. Clinical Trial.
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
Wolfe CR, Tomashek KM, Patterson TF, Gomez CA, Marconi VC, Jain MK, Yang OO, Paules CI, Palacios GMR, Grossberg R, Harkins MS, Mularski RA, Erdmann N, Sandkovsky U, Almasri E, Pineda JR, Dretler AW, de Castilla DL, Branche AR, Park PK, Mehta AK, Short WR, McLellan SLF, Kline S, Iovine NM, El Sahly HM, Doernberg SB, Oh MD, Huprikar N, Hohmann E, Kelley CF, Holodniy M, Kim ES, Sweeney DA, Finberg RW, Grimes KA, Maves RC, Ko ER, Engemann JJ, Taylor BS, Ponce PO, Larson L, Melendez DP, Seibert AM, Rouphael NG, Strebe J, Clark JL, Julian KG, de Leon AP, Cardoso A, de Bono S, Atmar RL, Ganesan A, Ferreira JL, Green M, Makowski M, Bonnett T, Beresnev T, Ghazaryan V, Dempsey W, Nayak SU, Dodd LE, Beigel JH, Kalil AC; ACTT-4 Study Group. Wolfe CR, et al. Among authors: kim es. Lancet Respir Med. 2022 Sep;10(9):888-899. doi: 10.1016/S2213-2600(22)00088-1. Epub 2022 May 23. Lancet Respir Med. 2022. PMID: 35617986 Free PMC article. Clinical Trial.
Oncolytic Viruses and Cancer Immunotherapy.
Malhotra J, Kim ES. Malhotra J, et al. Among authors: kim es. Curr Oncol Rep. 2023 Jan;25(1):19-28. doi: 10.1007/s11912-022-01341-w. Epub 2022 Nov 28. Curr Oncol Rep. 2023. PMID: 36441447 Review.
2,700 results